Model generalizability considerations in development and evaluation of SaMD.

IF 1.3 4区 医学 Q4 PHARMACOLOGY & PHARMACY
Ning Leng, Yichen Lu, Jane Fridlyand, Tiffany Tang, Ting Qi, Yingying Wei, Rodrigo Rojo Sanchez, Noah Simon, Gregory Alexander
{"title":"Model generalizability considerations in development and evaluation of SaMD.","authors":"Ning Leng, Yichen Lu, Jane Fridlyand, Tiffany Tang, Ting Qi, Yingying Wei, Rodrigo Rojo Sanchez, Noah Simon, Gregory Alexander","doi":"10.1080/10543406.2026.2729800","DOIUrl":null,"url":null,"abstract":"<p><p>Software as a Medical Device (SaMD) has been transforming medical practices by improving patient care with more precise and timely information. Key capabilities of SaMD are often powered by Artificial Intelligence (AI) algorithms. However, significant challenges arise in developing robust algorithms for SaMD, as these algorithms can perform well during development but poorly during pivotal validation studies. Due to the rapid advancement in medical research, data from new studies or real-world sources are likely to differ significantly from the legacy data used for development; with this, algorithms need to account for these potential data heterogeneity differences. This paper discusses the shortcomings of conventional cross-validation methods widely used in SaMD algorithm development and demonstrates model performance overestimation in the presence of data heterogeneity. To address this bias, we propose a simple and practical alternative: the leave-one-set-out (LOSO) cross-validation method. Additionally, we outline best practices for designing independent validation pivotal studies.</p>","PeriodicalId":54870,"journal":{"name":"Journal of Biopharmaceutical Statistics","volume":" ","pages":"1-13"},"PeriodicalIF":1.3000,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biopharmaceutical Statistics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10543406.2026.2729800","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Software as a Medical Device (SaMD) has been transforming medical practices by improving patient care with more precise and timely information. Key capabilities of SaMD are often powered by Artificial Intelligence (AI) algorithms. However, significant challenges arise in developing robust algorithms for SaMD, as these algorithms can perform well during development but poorly during pivotal validation studies. Due to the rapid advancement in medical research, data from new studies or real-world sources are likely to differ significantly from the legacy data used for development; with this, algorithms need to account for these potential data heterogeneity differences. This paper discusses the shortcomings of conventional cross-validation methods widely used in SaMD algorithm development and demonstrates model performance overestimation in the presence of data heterogeneity. To address this bias, we propose a simple and practical alternative: the leave-one-set-out (LOSO) cross-validation method. Additionally, we outline best practices for designing independent validation pivotal studies.

SaMD开发与评价中的模型通用性考虑。
软件即医疗设备(SaMD)通过提供更精确和及时的信息来改善患者护理,从而改变了医疗实践。SaMD的关键功能通常由人工智能(AI)算法提供支持。然而,在为SaMD开发鲁棒算法时出现了重大挑战,因为这些算法在开发期间表现良好,但在关键验证研究期间表现不佳。由于医学研究进展迅速,来自新研究或真实来源的数据可能与用于发展的遗留数据有很大不同;因此,算法需要考虑这些潜在的数据异质性差异。本文讨论了SaMD算法开发中广泛使用的传统交叉验证方法的缺点,并论证了存在数据异质性时模型性能的高估。为了解决这种偏差,我们提出了一种简单实用的替代方法:留一套交叉验证方法(LOSO)。此外,我们概述了设计独立验证关键研究的最佳实践。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Biopharmaceutical Statistics
Journal of Biopharmaceutical Statistics 医学-统计学与概率论
CiteScore
2.50
自引率
18.20%
发文量
71
审稿时长
6-12 weeks
期刊介绍: The Journal of Biopharmaceutical Statistics, a rapid publication journal, discusses quality applications of statistics in biopharmaceutical research and development. Now publishing six times per year, it includes expositions of statistical methodology with immediate applicability to biopharmaceutical research in the form of full-length and short manuscripts, review articles, selected/invited conference papers, short articles, and letters to the editor. Addressing timely and provocative topics important to the biostatistical profession, the journal covers: Drug, device, and biological research and development; Drug screening and drug design; Assessment of pharmacological activity; Pharmaceutical formulation and scale-up; Preclinical safety assessment; Bioavailability, bioequivalence, and pharmacokinetics; Phase, I, II, and III clinical development including complex innovative designs; Premarket approval assessment of clinical safety; Postmarketing surveillance; Big data and artificial intelligence and applications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书